8-K: Moderna Reports Q1 2024 Results with $167 Million Revenue, Prepares for Key Vaccine Launches

Moderna's first quarter 2024 results show a significant revenue drop to $167 million, alongside a net loss of $1.2 billion, as the company prepares for the launch of its RSV vaccine and a new Spikevax formula.

Summary

• Moderna reported first quarter 2024 revenue of $167 million, a significant decrease from $1.9 billion in the same period last year, primarily due to reduced COVID-19 vaccine sales.
• The company experienced a net loss of $1.2 billion, compared to a net income of $79 million in the first quarter of 2023, resulting in a diluted loss per share of $(3.07).
• Cost of sales was $96 million, including $30 million in inventory write-downs and $27 million in unutilized manufacturing capacity costs.
• Research and development expenses decreased by 6% to $1.1 billion, while selling, general, and administrative expenses decreased by 10% to $274 million.
• Moderna reaffirmed its 2024 product sales outlook of approximately $4 billion, with about $0.3 billion expected in the first half of the year.
• The company anticipates initial regulatory approvals for its RSV vaccine in the first half of 2024 and is targeting a fall 2024 launch in the U.S.
• Moderna is advancing multiple vaccine programs, including those for Epstein-Barr virus, Varicella-Zoster virus, and norovirus, towards Phase 3 clinical trials.
• The company's cash, cash equivalents, and investments totaled $12.2 billion as of March 31, 2024, down from $13.3 billion at the end of 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and future product launches, the significant revenue decline and net loss in Q1 2024 are concerning. The company is also facing increased competition and market uncertainty. The sentiment is therefore cautiously negative.

Positives

• Moderna is preparing for the launch of its RSV vaccine and a new Spikevax formula, which are expected to contribute to future revenue.
• The company is advancing multiple vaccine programs towards Phase 3 clinical trials, indicating a strong pipeline.
• Moderna has secured a contract to supply 12.5 million mRNA COVID-19 vaccines to Brazil.
• The company is participating in the EU Health Emergency and Response Authority's tendering procedure for up to 36 million doses of mRNA COVID-19 vaccines per year for up to four years.
• Moderna's RSV vaccine will be the only pre-filled syringe product available, offering a competitive advantage.
• The company is focusing on AI technologies to streamline operations and enhance productivity.
• Moderna has a strong cash position of $12.2 billion.

Negatives

• First quarter revenue decreased significantly to $167 million, a 91% drop compared to the same period in 2023.
• The company reported a net loss of $1.2 billion for the first quarter of 2024.
• Diluted loss per share was $(3.07) for the first quarter of 2024.
• Cost of sales as a percentage of net product sales increased to 58% in the first quarter of 2024, compared to 43% in the first quarter of 2023.
• The company's cash position decreased by $1.1 billion during the first quarter of 2024.
• Moderna is discontinuing development of its preclinical PD-L1 program.

Risks

• The company's revenue is heavily reliant on the success of its respiratory vaccine franchise.
• There are risks associated with regulatory approvals and market acceptance of new vaccines.
• The company faces competition in the vaccine market.
• The company's financial performance is subject to fluctuations in sales and operating expenses.
• The company's cash position decreased by $1.1 billion during the first quarter of 2024, primarily due to research and development expenses and operating activities.

Future Outlook

Moderna reaffirms its 2024 expected revenue of approximately $4 billion from its respiratory franchise and anticipates numerous product milestones this year across its vaccines and therapeutics portfolio. The company expects approximately $0.3 billion in net sales in the first half of the year, reflecting the seasonality of the respiratory business. Year-end cash and investments for 2024 are projected to be approximately $9 billion.

Management Comments

• Stéphane Bancel, Chief Executive Officer of Moderna, stated that the company is exercising financial discipline and intensifying its focus on building and utilizing AI technologies to further streamline operations and enhance productivity.
• He also mentioned that with 10 late-stage programs and additional new programs advancing toward pivotal studies, the company expects numerous product milestones this year across its vaccines and therapeutics portfolio.

Industry Context

Moderna's results reflect the shift from a pandemic-driven market to a more seasonal respiratory vaccine market. The company is focusing on expanding its pipeline beyond COVID-19, with new programs in RSV, flu, and other infectious diseases. The company is also investing in AI to improve efficiency and reduce costs. The company is competing with other pharmaceutical companies in the vaccine market, including Pfizer and Sanofi.

Comparison to Industry Standards

• Moderna's revenue decline is significant compared to the previous year, reflecting the reduced demand for COVID-19 vaccines, which is a trend seen across the industry as the pandemic transitions to an endemic phase.
• Pfizer, another major player in the COVID-19 vaccine market, has also reported a decline in COVID-19 vaccine sales, but their diversified portfolio has helped mitigate the impact.
• Sanofi, a competitor in the flu vaccine market, has a more established seasonal vaccine business, which provides a more stable revenue stream.
• Moderna's focus on mRNA technology and its pipeline of new vaccines and therapeutics positions it well for future growth, but it needs to successfully launch its new products to offset the decline in COVID-19 vaccine sales.
• The company's investment in AI and other technologies is in line with industry trends to improve efficiency and reduce costs.

Stakeholder Impact

• Shareholders are negatively impacted by the significant net loss and decreased revenue.
• Employees may be impacted by the company's focus on cost discipline and efficiency.
• Customers may benefit from the launch of new vaccines and therapeutics.
• Suppliers may be impacted by changes in the company's manufacturing and supply chain.
• Creditors may be impacted by the company's financial performance.

Next Steps

• Moderna is awaiting regulatory approvals for its RSV vaccine.
• The company is targeting a fall 2024 launch for its RSV vaccine in the U.S.
• Moderna intends to file for regulatory approval of its seasonal flu vaccine in 2024.
• The company is engaging with regulators on next steps for its next-generation COVID-19 vaccine.
• Moderna anticipates data from the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 in 2024.
• The first interim analysis for the evaluation of vaccine efficacy for its CMV vaccine is expected as early as the end of 2024.
• The company expects to advance its PA and MMA programs into registrational studies in 2024.

Key Dates

Keywords

Moderna, mRNA, Vaccine, COVID-19, RSV, Spikevax, Clinical Trials, Financial Results, Revenue, Net Loss, Pharmaceuticals, Biotechnology